These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 27120449)
1. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study. Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449 [TBL] [Abstract][Full Text] [Related]
2. Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand. Teeranaipong P; Sirivichayakul S; Mekprasan S; Ruxrungtham K; Putcharoen O J Int AIDS Soc; 2014; 17(4 Suppl 3):19740. PubMed ID: 25397485 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana. Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907 [TBL] [Abstract][Full Text] [Related]
7. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD; AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563 [TBL] [Abstract][Full Text] [Related]
8. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781 [TBL] [Abstract][Full Text] [Related]
9. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine. Theys K; Camacho RJ; Gomes P; Vandamme AM; Rhee SY; Clin Microbiol Infect; 2015 Jun; 21(6):607.e1-8. PubMed ID: 25704446 [TBL] [Abstract][Full Text] [Related]
10. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807 [TBL] [Abstract][Full Text] [Related]
12. Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina. Córdova E; Loiza E; Porteiro N; Mingrone H Enferm Infecc Microbiol Clin; 2011; 29(6):428-31. PubMed ID: 21592625 [TBL] [Abstract][Full Text] [Related]
13. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793 [TBL] [Abstract][Full Text] [Related]
14. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR]. Domingo P; Ribera E Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530 [TBL] [Abstract][Full Text] [Related]
15. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H; Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492 [TBL] [Abstract][Full Text] [Related]
16. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects. Porter DP; Kulkarni R; Fralich T; Miller MD; White KL HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187 [TBL] [Abstract][Full Text] [Related]
17. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090 [TBL] [Abstract][Full Text] [Related]
18. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana. Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264 [TBL] [Abstract][Full Text] [Related]
19. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. Asahchop EL; Wainberg MA; Oliveira M; Xu H; Brenner BG; Moisi D; Ibanescu IR; Tremblay C AIDS; 2013 Mar; 27(6):879-887. PubMed ID: 23262501 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). Scherrer AU; Hasse B; von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Bucher HC; Ledergerber B; Günthard HF HIV Med; 2009 Nov; 10(10):647-56. PubMed ID: 19732174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]